Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start. 

According to the FDA, using these devices without following manufacturer recommendations could lead to “serious injuries or death." 

The FDA’s final decision was based largely on positive results from the ADVENT clinical trial, which compared treatment with the Farapulse PFA System to the current standard of care.

The group's annual meeting heads to Atlanta this April. TAVR, GLP-1 agonists, medical imaging guidance and blood pressure control are just some of the topics that will be presented during late-breaking sessions.

The two neighboring practices have joined forces to provide improved cardiovascular care for patients throughout the Sunshine State. 

STS announced the news Monday at its annual meeting in San Antonio. Jennifer C. Romano, MD, MS, is officially the first female president in the organization's 60-year history.

The device, which also received Great Britain’s UKCA marking, was specifically designed to be less bulky and easier to wear than other wearable cardioverter-defibrillators.

Researchers tracked data from more than 500 PCI patients, exploring the cost-effectiveness and safety of multiple treatment options.